Study type: In vivo/preclinical · Status: Verified against declared source

Cerebrolysin Use in Patients with Liver Damage-A Translational Study

2022

Study scale: Non-alcoholic fatty liver disease (NAFLD) is a global health problem with a prevalence of approximately 25% worldwide [1].

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Given the prevalence of non-alcoholic fatty liver disease (NAFLD), there is a high chance that some of these patients can develop acute life-threatening events such as stroke.

Methods

For tissue harvesting we used a method with the least impact on microglial activation [23].

Scale or participants

Non-alcoholic fatty liver disease (NAFLD) is a global health problem with a prevalence of approximately 25% worldwide [1].

Key findings

The treatment of acute life-threatening events in patients suffering from chronic pathologies is problematic, as physicians need to consider multisystemic drug effects.

Limitations and uncertainty

Non-alcoholic fatty liver disease (NAFLD) is a global health problem with a prevalence of approximately 25% worldwide [1].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.